Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the U.S. Food and Drug ...

Tech improvements have benefited the chronic illness community, writes columnist Anna Jeter, who shares things she uses to ...

Strong positive interim data from an earlier Phase 3 trial has led to early cessation of Merck’s pulmonary arterial ...

Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among ...

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial ...

Highlight box Key findings • The bibliometric analysis summarized the major areas and promising research directions on chronic thromboembolic pulmonary hypertension (CTEPH) over the past two decades.

CT scan-assessed high right ventricle-left ventricle ratio of the heart predicts major adverse cardiovascular events in PH ...

Implementing the ventilator-associated events (VAE) prevention protocol at Community Health Network has yielded remarkable results. After two years of ...

Back to Healio In this episode, we dive into the early therapies and how our understanding of vascular physiology drastically changed the management of pulmonary hypertension.

Background: The use of appetite suppressants in Europe has been associated with the development of primary pulmonary hypertension (PPH). Recently, fenfluramine appetite suppressants became widely ...